A high-performance, user-centric estradiol patch
- Designed for adhesion and tolerability
- Built for real-world use
- Bio-equivalent, but meaningfully better
- Underpins the Hormonal Continuity™ system
Transdermal drug delivery, rebuilt
Building the future of transdermal drug delivery.
Today’s patches were built for short courses of treatment. Women on menopause hormone therapy need decades of uninterrupted care. LORAI Health is building a next-generation transdermal platform so therapy stays on, stays consistent, and stays available.
Two stories. One company.
Start with one. Scale to many.
Hormonal Continuity™
Category creation in women’s health. Menopause is the entry point: a chronic condition that requires continuous, uninterrupted therapy over decades.
Gen-2 LORAI Transdermal Platform
Infrastructure for a global delivery market. A compound-agnostic platform built on advanced materials, bioadhesive science and a proprietary 3D matrix.
The problem
Hormonal medicine was built for acute care. Women need life-long continuity.
Clinical guidelines have moved from five-year limits to long-term, even lifetime, use of menopause hormone therapy. Transdermal patches are clinically preferred, but unreliable in practice.
Acute-care system
- Short-term treatment
- Supply chains built for ad-hoc substitution
- Sub-par patch performance
Chronic-care reality
- 40+ year therapy
- Continuous use, high adherence dependency
- Zero tolerance for interruption
“My patients can’t get estrogen patches. Ones that they get don’t stick or irritate skin.”
Our approach
Sequenced approach with breakthrough materials innovation
A best-in-class estradiol patch first, then a platform that carries many molecules.
A delivery platform, not a single product
- Compound-agnostic architecture
- Controlled release, longer duration
- Skin-compatible, non-irritant materials
- Higher bioavailability
What makes us better
What we are designing for
50%lower dermal irritation versus generics
50%smaller: a discreet patch footprint
Day 4–7intact adhesion through multi-day wear
Future-prooffor compliance and supply stability
Design targets for the LORAI Gen-1 patch. Investigational; not yet evaluated by the FDA or TGA.
US operations
Research and development at the Delaware Innovation Space (DISI)
LORAI Health LLC develops the Gen-2 transdermal platform at DISI, the science incubator at DuPont’s Experimental Station in Wilmington, Delaware.
Leadership
Experience with execution and women’s health
Co-founder · Chief Executive Officer
Dr Raisa Monteiro
Raisa brings more than 20 years of experience in materials and biotechnology commercialization, partnerships, fundraising, and company building across startups, industry, and research institutions.
Stanford University · DuPont · KPMG
Chief Technology Officer
Dr Alex Ionkin
Alex brings deep experience in organic chemistry, polymers, adhesives, coatings, and advanced materials development, providing the technical leadership behind LORAI Health’s transdermal platform.
FXI · B. Braun · DuPont
Get in touch
Build the next generation of transdermal delivery with us.
We work with pharma partners, CDMOs, clinicians, and investors who share our view that continuous therapy deserves purpose-built delivery.